See "Focused therapies in CLL: mechanisms of resistance and strategies for administration" on site 471. Duvelisib was the 2nd PI3K inhibitor authorized because of the FDA, also depending on a section III randomized trial.a hundred thirty The efficacy and safety profile with the drug surface equivalent with Individuals of idelalisib, https://mbl7767789.nizarblog.com/32611318/about-link-alternatif-mbl77